glp-1 and seizures Low Blood Pressure: Symptoms, Risks, and Management 🔸 Should GLP-1 RAs be

The Phase 3 ATTAIN-1 trial had good results that led to this approval, but not all positive: 12.4% average weight loss (27.3 lbs) at highest dose Lower than the 15-20% weight loss seen with injectables Wegovy and Zepbound Nearly 1/4 of participants on the highest dose reported vomiting Vomiting rates are much higher than injectable GLP-1s However, there is likely a niche for Foundayo (along with the pill version of Wegovy) due to convenience: No refrigeration requirements or injection site reactions Eliminates barriers for patients avoiding injectables due to stigma, needle aversion, or storage constraints It's possible we could see this as a "maintenance" therapy after an initial injectable course

BPC-157 is a synthetic peptide compound commonly studied within laboratory and analytical research environments

Vegan | Plant-Based | Cruelty-Free | Free from Harsh Chemicals

Nonetheless, the long-term consequences of GLP-1 RA use in adolescents remain under-researched, highlighting the need for future studies on safety and effectiveness in adolescent populations

Clean surfaces you touch frequently such as telephones, TV remotes, and computer keyboards with sanitizer